Company Overview of AlphaVax, Inc.
AlphaVax, Inc. produces vaccines for infectious disease prevention and cancer immunotherapy. Its alphavccine candidates targeting human cytomegalovirus, influenza A virus, or HIV-1 are in clinical trials. The company’s products also include AVX901, a HER2-VRP vaccine for a Phase I study in advanced and metastatic breast cancer. Its alphavaccine technology is based on its replicon vector platform derived from attenuated strains of the alphavirus, Venezuelan equine encephalitis virus. The company’s alphavaccine applications include prophylactic vaccines, therapeutic vaccines, tumor immunotherapy, and biodefense. Its products are used in various cancer treatments, such as colon cancer, breast c...
2 Triangle Drive
P.O. Box 110307
Research Triangle Park, NC 27709-0307
Founded in 1997
Key Executives for AlphaVax, Inc.
Vice President of Business Development
Senior Director of Quality Assurance
Chairman of CMV Advisory Board and Vice President of Research
Compensation as of Fiscal Year 2014.
AlphaVax, Inc. Key Developments
Harrisvaccines Secures Exclusive Rights from AlphaVax, Inc. to Develop RNA Particle Vaccines for All Diseases in Companion Animals
Oct 29 13
Harrisvaccines announced it has expanded its exclusive license agreement with AlphaVax, Inc. to include all companion animals diseases, in addition to all livestock animal diseases (swine, cattle, horses, poultry, and farmed aquatic animals). This announcement significantly expands the Harrisvaccines product portfolio, transforming it from a primarily production livestock-focused company to a full-service veterinary animal health company, developing vaccines for animals large and small. Harrisvaccines will begin its work in the companion animal realm by developing vaccines for a variety of respiratory diseases in dogs. Harrisvaccines' RNA Particle (RP) Platform technology utilizes a genetic sequence of specific viruses, which can be submitted electronically, to create a vaccine. Harrisvaccines can use this technology to develop strain-specific vaccines in just a matter of weeks, allowing for rapid response to disease outbreaks. As diseases are constantly evolving, this is crucial to containment and eradication efforts.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries